Relia Biotech

ReLIA Biotech & ReLIA Diagnostic Systems, Inc. sincerely invite all of our business partners and friends to visit us at 3G92-4 during MEDICA - Leading International Trade Fair from 13-16th, Novermber, 2023 in Duesseldorf, Germany.

ReLIA Biotech will bring emergency POCT solutions from heart failure test, heart attack test, acute coronary syndrom test to acute inflammation tests.

For more details, welcome to contact with us as below:
: www.reliabiotech.com/en
: [email protected]
：+86 135 6443 8359

is a severe systemic response that is usually caused by , but it is not just a problem of the infection itself, but the body's extreme response to the infection. Sepsis can cause damage to multiple organ functions and even organ failure, which is life-threatening.

Relia Biotech could provide 5 different and combo biomarkers (bi-directional POCT tests and FIA POCT tests) under below:

Procalcitonin ( ),
C-reactive Protein ( ),
Interleukin-6 ( ),
Serum amyloid A ( ),
Heparin-Binding Protein（ ）

For more details, please feel free to contact with us:
: www.reliabiotech.com/en
: [email protected]
WhatsApp/WeChat: +86 13564438359

-6

Relia Biotech sincerely invite all of our friends and business partners to visit us (Booth number: H6.B33) at Medlab Asia & Asia Health 2023 in , Thailand during 16-18th, August.

Make an appointment with us ahead and our team will be waiting for your coming.....

Another full automatic immunoassay fluroscence analyzer TZ310 (dry chemistry method) was installed in Huashan Hopital, Fudan University, Shanghai. (one of Chinese top 10 hospitals)

Relia Biotech Fluroscence immunoassay analyzer TZ310:
1. full-automatic benchtop device
2. 75-120 tests/hour
3. running time: 2-8 minutes
4. up to 10 tests running at the same time
5. Whole Blood sample could be run directly without any need of purification, centrifuge, dilution.

For more details, please feel free to contact with us:
: www.reliabiotech.com/en
: [email protected]
/WeChat: 135 6443 8359

Welcome to visit us at Beijing International Life and Health Industry Expo in Beijing during 11-13rd, July. During the exhibition, Relia Biotech will demo our full solution on quantitative tests, especially on tests and tests.

is a regulatory protein of muscle tissue contraction, located on the thin myofilament of contractile protein, and plays an important regulatory role in the process of muscle contraction and relaxation; it contains 3 subtypes: fast-response type and slow-response type and cardiac troponin.
Cardiac troponin is present only in and the widely biomarkers are cadrdiac troponin I and cardiac troponin T.

Relia Biotech high-sensitivity Fluroscence Immunoassay troponin I POCT test kit:

1. Minimum working range could reach up to 0.02ng/mL

2. High correlation with I2000 and DXI8000.

3. NO need to dilute even whole blood samples, No need to use Buffer Solution (increase sensitivity and reduce cross contamination)

4. Inside incubation

5. Running time: 2-8 minutes

For further details or interest, welcome to let us know.

On May 17th, we celebrate World Hypertension Day, a day dedicated to highlighting the importance of monitoring blood pressure and bringing global awareness to the 1 billion people living with high blood pressure worldwide.

has direct relations with disease. Relia Biotech has full items on tests as below:
1. MPO (myeloperoxidase) test
2. ST-2 test
3. s-100β test
4. cTnT test
5. NT-proBNP and BNP test
6. D-Dimer test
7. Heart-Type Fatty Acid Binding Protein Test (HFABP)
8. Fibrin/Fibrinogen Degradation Product Test (FDP)
9. hs-cTnI
10. Lp-PLA2
11. CK-MB, cTnI, Myo single and combo tests

:
A. Applicable sample: whole blood, serum, plasma

B. NO need for dilution, NO buffer needed

C. Detecton time: 2-8 minutes
(fastest running time on cardiac LFT tests)

For more details, welcome to contact with us as below:
: [email protected]
/WeChat: +86 13564438359
: www.reliabiotech.com/en

Get to know Relia Biotech fluroscence immunoassay ( ) analyzer , the portable device with flexible application situations:

1. Three indepedent fluroscent detection channels (tailor made is avalable)

2. Incubation inside, no need to manually transfer the cartriage

3. Applicable samples: plasma, serum, whole blood, urine...

4. Fastest detection time: ≤8 minutes (include Whole Blood Sample)

5. Wider configuration under different testing pannels ( cardiac biomareker, inflammation, renal & gastric function, hormone, infection disease...)



For more details, please contact:
: www.reliabiotech.com/en
: [email protected]
/WeChat: 135 6443 8359

Welcome to visit China Medical Equipment Conference & Medical Equipment Exhibition held in Chongqing, China 2023 during 26-28th, April.

Relia Biotech booth: B09, Hall N2.

This year, we will launch our newly full automatic dry chemistry fluroscence immunoassay analyzer (FIA) there with various of flexible new biomarkers on cardiovascular diseases like LP-PLA2, ST-2, BNP, cTNI&H-FABP, c-TNT, etc.

For further information, please feel free to contact:
: www.reliabiotech.com/en
: [email protected]
: +86 135 6443 8359

Founder of Relia Biotech:

William J. Rutter (born August 28, 1928) is an American biochemist who cofounded the early biotechnology company Chiron Corporation together with Edward Penhoet and Pablo DT Valenzuela. As Chairman of the Department of Biochemistry and Biophysics of the University of California, San Francisco, Rutter helped establish that department as a leader in the academic side of the biotechnology during the San Francisco Bay Area biotech boom of the 1980s.

Rutter spent a short time in the United States Navy and one year Brigham Young University, before completing a B.A. (1949) in biochemistry at Harvard University. He earned an M.S. (1950) from University of Utah and a PhD (1952) from the University of Illinois with a dissertation on galactosemia. Between 1952 and 1968, Rutter held positions at the University of Wisconsin, the Karolinska Institutet, University of Illinois, Stanford University, and University of Washington. In 1969, he moved to the University of California, San Francisco (UCSF), where he led the Department of Biochemistry and Biophysics until 1982. From 1983 until 1989, Rutter was Director of the Hormone Research Institute at UCSF.

In 1996, Rutter won the 2nd Annual Heinz Awards in Technology, the Economy and Employment.

In the year of 2001, Rutter founded ReLIA Diagnostic Systems, Inc. (in brief: Relia BiotechReLIA Biotech) , a typical immunodiagnostic quantitative POCT manufacturer specialized in cardiac biomarkers, inflammation, hormone, renal functions and some other biomarker tests.

In the year of 2003, he received the Biotechnology Heritage Award, from the Biotechnology Industry Organization (BIO) and the Chemical Heritage Foundation because of his contributions to , especially for Point-of-care-testing (POCT).

Rutter and his team’s visit to Relia Biotech:

Today is 18th World Kidney Day and this year, the theam is Kidney Health for All.

The significant impact of disastrous events, be they local (earthquake, floods, war, extreme weather) or global (the COVID-19 pandemic), affects the functioning and living conditions of the community as a whole, by definition resulting in one or more of the following consequences: human, material, economic and environmental losses and impacts. Those affected by chronic disease, of which kidney patients represent more than 850 million people worldwide, are particularly affected by these disruptions, as the ability to access proper diagnostic services, treatments and care is greatly jeopardized.

Accordfing to Lancet data collected in 2020, nearly 1/3 global CKD (chronic kidney disease) patients are located in China and India, with the population of 132 million and 113 million respectively. This means, even in China, there will be 1 CKD patient for each 10 people. Early screening would be an important way for CKD diagnosis and treatent and ReLIA Biotech, a specialized immunodiagnostic POCT manufacturer, supplies the quantitative items as the following:

1. Cys-C
2. NGAL
3. MAU
4. β2-MG
5. NGAL+MAU
6. C-Pepitide + Insulin

Test time: 2-8 minutes
Sample: Serum, whole blood, plasma....

For more details, pls feel free to contact:
Web : www.reliabiotech.com/en
E-mail: [email protected]

Right now, especially Flu-A becomes one of the concerns in the public after COVID-19 in many parts of the world.

Many people got cough, headache, runny nose and don't know the reason.
Is it bacterial infection or virus infection? How serious it is? What shall we do to face it?

Here is some analysis from Relia Biotech about inflammation biomarkers and follow us to know more!

Inflammation Biomarkers (PCT, SAA, CRP) When we speak of Inflammation Biomarkers, we need to know what is inflammation in medical field. The human body is like a well-functioning country, viruses and bacteria are the two most common types of "invading" enemies.

Relia Biotech RF810 (Fluorescence Immunoassay Analyzer) is a multi-channel POC analyzer and has 3 independent fluorescence channels (up to 10 channels by customization) with adjustable stable incubation temperature (18℃±0.25℃).

Running time of this analyzer could be made within 8 miniutes (include whole blood samples).

NO need for extra pretreatment (include whole blood samples) thus, ensures more accurate test results.

Application: Emergency department, clinical laboratory, ICU, CCU, cardiology, ambulance, etc.

Distributors needed and for further information, please contact with us as below:
Web: www.reliabiotech.com/en
Mail: [email protected]
Whastapp/Wechat: +86 13564438359

Always be alert to abnormal biomarkers during the post-pandemic period:

◆During the COVID-19 post-pandemic period, the real danger is the elderly, the unvaccinated population, and the population with chronic underlying diseases such as disease. These groups are prone to severe and critical illness. Therefore, monitoring of enzymes is recommended in multiple versions of the diagnosis and treatment plan.

◆In a meta-analysis, the incidence of Covid-19 combined with heart disease was around 30%, and the occurrence or related factors of acute cardiac injury ( ) was an important in-hospital mortality factor for COVID-19 patients (especially critically ill patients) , in which hs-cTnI, NT-proBNP, IL-6, etc. are independent risk factors for death in critically ill patients, and the mortality rate of patients with elevated hs-cTnI and NT-proBNP is higher than that of patients with elevated other single indicators.

Relia Biotech has full items of myocardical biomarkers like (CK-MB, c-TnI, MYO, hs c-TnI, c-TnT, H-FABP, ST-2, BNP, NT-proBNP, HBP, etc) based on quantitative fluorescence immunoassay and colloidal gold POCT platform.

For more information, please contact with us as below:
Web: www.reliabiotech.com/en
Mail: [email protected]
Whastapp/Wechat: +86 13564438359

Ref:
1. http://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf.
2. Souyris S, Hao S, Bose S, et al. Detecting and mitigating simultaneous waves of COVID-19 infections. Sci Rep. 2022 Oct 6;12(1):16727.
3. REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 2021;384:1491-502.

After China lifted up SARS-CoV-2 test and restrictions, every day, there are millions of new cases popped up and most of them have mild symptoms or are the .

On 3rd, August, 2022, there was an article: Heart disease after COVID: what the data say published on journal and according to its research, the high risk of being infected with cardiovascular diseases would go with the patients even after recovery for several months. This means, the risk of diseases increase would be an important sequel after COVID-19.

These days, medical department chief physician professor Wu Wei from the 1st affiliated hospital of Guangzhou University of Chinese Medicine in China suggests all massive chronic cardiovascular diseases patients should keep monitoring their cardiovascular status. They need continuously take medicine and not stop. Once get infected with COVID-19, patients should take cardiovascular drugs as well as antipyretic drugs if they have fever. Severe symptoms should go to hospital immediately.

As one of the most important tools to monitor cardiovascular status, Relia Biotech POCT platform (bidirectional colloidal gold platform and fluorescence immunoassay platform) could largely increase the testing efficiency (7-15 minutes) with a reliable quality for various cardiovascular diaseases. Our cardiovascular detection biomarkers include: , -cTNI , , -MB, -Dimer, , -proBNP, H-FABP, -2, -100β, -PLA2, , , etc.

For more information, please contact with us as below:
Web: www.reliabiotech.com/en
Mail: [email protected]
Whastapp/Wechat: +86 13564438359

plays a role in many different diseases, including short-term issues and more chronic inflammatory disorders. Because of this, scientists have worked hard to find “ ” of .

Through a blood test or other type of test, clinicians can get information about different aspects of inflammation in the body. These tests measure are what called .

The chart below is a good example to show the whole blood concentration for each of the inflammation biomarkers.

Relia Biotech (Point-of-Care Testing) inflammation biomarkers kits (CRP, PCT, IL-6, HBP, SAA etc) based on , would be a good platform for clinicians to diagnose, treat and assess almost every patient.

For further information, pls feel free to contact us as below:
Web: www.reliabiotech.com/en
Mail: [email protected]
Whatsapp/Wechat: 135 6443 8359

It is a pity that the famous actor Mr. Lu Shuming who played Guan Yu in the traditional Romance of the Three Kingdoms (one of the Chinese four great classical masterpieces) died at the age of 66 because of (acute myocardial infarction) today.

AMI (acute myocardial infarction) is a kind of mycardial necrosis caused by acute and persistent ischemia and hypoxia of coronary artery. According to the Chinese clinical data, only in China, there is over 1 million new AMI (acute myocardial infarction) every year and this means, for every 18-20 seconds, there is a new case of heart attack. What's worse, 1 in 3 of the cases ends up in death and the death rate is over 30%. According to the research, some cardiovascular diseases begin to show a younger trend and the age below 45 years old become more and more.

There are some symptoms for AMI (acute myocardial infarction):
1. chest pain, chest tightness and followed by back pain, discomfort in both upper extremities, sweating, etc. ( usually occurs during activities or at night or at rest)
2. continuous chest pain and chest tightness last for 3 to 5 minutes each time; it can be improved by rest or stop activities, and some patients can be relieved by taking nitroglycerin

There are also some other triggering factors that can cause (acute myocardial infarction) like: emotional agitation, overwork, heavy smoking, alcohol consumption, sudden changes in climate. Some lifestyles like light diet, do not over exercise, release pressure in time could largely reduce the chance of heart attack.

At the same time, early diagnosis is pretty important. Once there is any similar case around you and your families, it is suggested to make early detection. Relia Biotech, a professional manufacturer has many biomarker kits for the early detection of (acute myocardial infarction), like cardiac-Troponin I( ), cardiac-Troponin T ( ), Creatine Kinase Isoenzymes( ), Myoglobin( ), etc.
All of the items are based on fluroscence immunoassay ( ), colloidal gold lateral flow test ( ) for quantitative diagnosis.

For any of the interest or question, welcome to contact with us as below:
Web: www.reliabiotech.com/en
Mail: [email protected]
Wechat/Whatsapp: 135 6443 8359

Relia Biotech is glad to attend (China Association of Clinical Laboratory Practice Expo) exhibition held in Nanchang City, Jiangxi Province, China during 26th-28th, Octobber. Our booth number is A1-0520.

At this exhibition, Relia Biotech launches some new products for the dry fluroscence immunoassay solution on disease, function, diseases and even panel disease quantitative tests kits.

Welcome to visit us there and again, our booth number is: A1-0520

Lighten up your life, shine a light on your joys, burn away your sadness, and make every relationship chocolatey. Relia Biotech wish all of our Indian partners and friends a more successful, joyful and healthier life and happy Diwali 2022!

Relia Biotech basic knowledge about heart failure:

Natriuretic peptides are substances made by the heart.
Two main types of these substances are brain natriuretic peptide ( ) and N-terminal pro b-type natriuretic peptide (NT-proBNP).

Normally, only small levels of and are found in the bloodstream. High levels can mean your heart isn't pumping as much blood as your body needs. When this happens, it's known as heart failure, sometimes called congestive heart failure.

The main purpose of or testing is to see if the blood levels of these proteins are within the expected range for a healthy person. These tests are most commonly used for diagnosis but may be involved in other health assessments.

Diagnosis is the process of finding the underlying cause of symptoms. BNP and NT-proBNP tests are often used to determine if a patient has heart failure. Heart failure is a condition in which the heart is not pumping blood properly to the rest of the body, but it does not mean that the heart has stopped.

People with congestive heart failure may experience various symptoms, including swelling and shortness of breath. However, these symptoms can be caused by many other conditions besides heart failure. and testing can be used to help find out if heart failure or some other condition is the cause of a patient’s symptoms.

and testing may also be used to evaluate people who have already been diagnosed with congestive heart failure. In these patients, testing may be ordered to assess the severity of the disease and its likely course or prognosis. Less often, or tests may be considered when determining what type of treatment to prescribe or when monitoring a patient’s health over time.

Relia Biotech has total solution for heart failure quantitative test diasgnosis by and or even other combo tests with other biomarkers based on Relia Biotech self-made test cards and analyzers.

For more information, please feel free to contact with us!

Web: www.reliabiotech.com/en
Mail: [email protected]
Whatsapp/Wechat: +86 135 6443 8359

Acute coronary syndrome ( ) is a constellation of clinical symptoms caused by acute myocardial ischemia. Patients with are subdivided into two major categories based on the 12-lead electrocardiogram (ECG) at presentation:
1. Those with ST-elevation myocardial infarction (STEMI)
2. Those who present with ST-segment depression, T-wave changes, or no ECG abnormalities (non-ST elevation ACS, NSTEACS).

NSTEACS includes both unstable angina and non-ST elevation myocardial infarction (NSTEMI), which can be detected through biomarkers for myocardial necrosis.

Myocardial necrosis is accompanied by the release of structural proteins and other intracellular macromolecules into the cardiac interstitium as a result of compromise of the integrity of cellular membranes.

Relia Biotech based / combo biomarker quantitative test is a useful tool to reach and early diagnose of myocardial necrosis.

For more information and interest, please feel free to contact:
Mail: [email protected]
Whatsapp/Wechat: +86 135 6443 8359
Web: www.reliabiotech.com/en

Relia Biotech full automatic analyzer is a portable and smart immunoassay diagnostic analyzer that could do the test for the panels as below flexibly:

1. Cardic Markers (MYO, CK-MB, c-Tnl, MPO, HFABP, ST-2, etc)
2. Coagulation ( D-Dimer, Fibrinogen/Fibrin Degradation)
3. Inflammation (SAA, CRP, hs-CRP, IL-6, PCT, etc)
4. Fertility (PROG, β-HCG, AMH)
5. Diabetes & Renal Function (NGAL, MAU, Cys-C, β-2 MG, etc)
6. Infectious diseases (COVID-19 antigen test kits, neutrolizing antibody, etc)

All of the items are marked and more items will be launched soon.

For more details, feel free to contact:

Web: www.reliabiotech.com/en
E-mail: [email protected]

Relia Biotech smart analyzer :

A portable, compact analyzer that could use low volume sample of , , , or even to present quantitative results within 8 minutes for the panels as below:

1. Cardic Markers (MYO, CK-MB, c-Tnl, MPO, HFABP, etc)

2. Coagulation ( D-Dimer)

3. Inflammation (SAA, CRP, hs-CRP, IL-6, PCT, etc)

4. Fertility (PROG, β-HCG)

5. Diabetes & Renal Function (NGAL, MAU, Cys-C, β-2 MG, etc)

6. Infectious diseases (COVID-19 antigen test kits, neutrolizing antibody, etc)

All of the items are marked and more items will be launched soon.

We are looking for global distributors and any interest, pls feel free to contact:

E-mail: [email protected]

Relia Biotech full automatic analyzer is a benchtop, compact analyzer that could automatic setting, detecting and reading results within 8 minutes for the panels as below:

1. Cardic Markers (MYO, CK-MB, c-Tnl, MPO, HFABP, etc)
2. Coagulation ( D-Dimer)
3. Inflammation (SAA, CRP, hs-CRP, IL-6, PCT, etc)
4. Fertility (PROG, β-HCG)
5. Diabetes & Renal Function (NGAL, MAU, Cys-C, β-2 MG, etc)
6. Infectious diseases (COVID-19 antigen test kits, neutrolizing antibody, etc)

All of the items are marked and more items will be launched soon.

For more details, feel free to contact:

Web: www.reliabiotech.com/en
E-mail: [email protected]

Relia Biotech Smart analyzer is a portable, compact FIA analyzer that could read results within 8 minutes for the panels as below:
1. Cardic Markers (MYO, CK-MB, c-Tnl, MPO, HFABP, etc)
2. Coagulation ( D-Dimer)
3. Inflammation (SAA, CRP, hs-CRP, IL-6, PCT, etc)
4. Fertility (PROG, β-HCG)
5. Diabetes & Renal Function (NGAL, MAU, Cys-C, β-2 MG, etc)
6. Infectious diseases (COVID-19 antigen test kits, neutrolizing antibody, etc)

All of the items are marked and more items will be launched soon.

For more details, feel free to contact:
E-mail: [email protected]

Since its foundation in 2001, Biotech has been at the forefront of research in point-of-care testing (POCT) technologies for field, with it’s primary research and development center located in Silicon Valley, California.

Currently, holds its Asian Pacific headquarters at the Shekou Free Trade Zone, Shenzhen, as well as large scale production and R&D centers in Shenzhen and Jiangsu. These centers have passed both the CFDA and ISO-13485 audit certification.

Under the guidance of Dr. Willian J. Rutter, our company’s founder, ReLIA has adhered to a diligent attitude towards research. We mold modern developments into technological advancement/systems, which promote rapid diagnostic services and improve the health and wellbeing of patients whilst simultaneously reducing medical costs.

Currently, ReLIA Biotech focuses on two platforms of rapid diagnostic tests:

1. Multi-functional immunoassay platform (test kits + LFT readers)
2. Immunofluorescence detection platform (test kits + FIA readers)

Both of these platforms cover the detection of biomarkers for , , and other infectious disease, etc.

Website: www.reliabiotech.com/en
Mail: [email protected]

Relia Biotech updated their business hours.

Relia Biotech updated their website address.